Financial Survey: SiBone (NASDAQ:SIBN) and Inogen (NASDAQ:INGN)

Inogen (NASDAQ:INGN) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Inogen and SiBone, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1	1	1	0	2.00
SiBone	1	0	5	0	2.67

Inogen currently has a consensus target price of $11.00, suggesting a potential upside of 76.00%. SiBone has a consensus target price of $25.00, suggesting a potential upside of 47.06%. Given Inogen’s higher possible upside, equities research analysts clearly believe Inogen is more favorable than SiBone.

Profitability

This table compares Inogen and SiBone’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-7.31%	-13.21%	-8.30%
SiBone	-11.24%	-12.86%	-9.43%

Institutional & Insider Ownership

89.9% of Inogen shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 1.5% of Inogen shares are held by company insiders. Comparatively, 4.0% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Inogen and SiBone”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$335.70 million	0.51	-$35.89 million	($1.01)	-6.19
SiBone	$193.58 million	3.81	-$30.91 million	($0.51)	-33.33

SiBone has lower revenue, but higher earnings than Inogen. SiBone is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Inogen has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Summary

SiBone beats Inogen on 8 of the 14 factors compared between the two stocks.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.